MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2022 International Congress

    Exploring Young people’s role in providing relief to grandparents affected with Alzheimer

    M. Busgopaul (Port Louis, Mauritius)

    Objective: In some families, children never know that their parents or grandparents are affected by the Parkinson’s Disease (PD). Whatever be the way that Movement…
  • 2022 International Congress

    Longitudinal brain perfusion changes correlated with UPDRS Total in a Phase I mesenchymal stem cell trial for Parkinson’s disease

    M. Schiess, J. Suescun, C. Adams, E. Tharp, K. Block, M. Doursout, T. Ellmore (Houston, USA)

    Objective: Explore changes in correlations between brain perfusion and UPDRS-Total (UPDRS-T) after a single infusion of allogeneic bone marrow-derived mesenchymal stem cells (MSC). Background: Our…
  • 2022 International Congress

    Clinical and biomarker characteristics of Huntington’s Disease patients recently proposed for huntingtin-lowering clinical trial inclusion

    G. Parkin, E. Thomas, C. Snell, A. Smirnova, A. Hall, L. Bohall, E. Churchill, J. Corey-Bloom (Irvine, USA)

    Objective: We investigated plasma NfL levels, as well as clinical measures, in Huntingtin (Htt)-mutation carriers 48 years of age and under, with a CAP score…
  • 2022 International Congress

    Neuroprotective trial design methodology for Parkinson’s: a scoping review

    E. King, M-L. Zeissler, P. Sharpe, T. Boey, F. O'Brian, D. Chapman, G. Rafaloff, K. Raphael, H. Venkatesh, C. Carroll (Plymouth, United Kingdom)

    Objective: To further understanding of the diversity and impact of trial design choices in trials of disease modifying therapy (DMT) in Parkinson’s disease (PD). Background:…
  • 2022 International Congress

    Vodobatinib, a potent, orally bioavailable brain-penetrating inhibitor of c-Abl as a potential neuroprotective agent for the treatment of Parkinson’s Disease

    R. Walsh, S. Piccoli, O. Hurko, N. Damle, V. Ramanathan, S. Yao, D. Love, S. Mandhane, R. Talluri (Princeton, USA)

    Objective: To compare and contrast nilotinib and vodobatinib regarding efficacy, brain penetration, and safety. Background: Preclinical evidence suggests that c-Abl is critical for pathogenesis of…
  • 2022 International Congress

    An AAV9 encoding human ABCD1 (SBT101) shows functional improvement following spinal cord delivery in a rodent model of adrenomyeloneuropathy

    A. Pujol, A. Bosch, I. Dijkstra, S. Kemp, Y. Jaspers, S. Verdés, S. Fourcade, C. Guilera, M. Leal-Julià, A. Onieva, V. Vasireddy, SW. Clark, D. Anderson, K. Kozarsky (Barcelona, Spain)

    Objective: SBT101 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy candidate delivering a functional copy of the human ABCD1 gene that is in development…
  • 2022 International Congress

    Nutritional Status of Patients with Parkinson’s Disease: Report from Indonesian Tertiary Referral Hospital

    SS. Musthafa, D. Tunjungsari, A. Tiksnadi (Jakarta, Indonesia)

    Objective: This study aimed to describe and determine the prevalence of nutritional status in outpatient Parkinson’s Disease (PD) patients. Background: Parkinson’s disease is the most…
  • 2022 International Congress

    Clinical Manifestations of Metabolic Syndrome in Parkinson’s Disease – Report from Indonesia Tertiary Referral Hospital

    DA. Soraya, D. Tunjungsari, A. Tiksnadi (Jakarta, Indonesia)

    Objective: The study aims to determine the prevalence of metabolic syndrome and related factors in Parkinson's disease (PD). Background: Parkinson's disease is a neurodegenerative disorder,…
  • 2022 International Congress

    Sex differences in vascular risk factors for Parkinson’s disease

    K. Tsutsumi, E. Shah, A. Siddiqui, I. Attaripour (Orange, USA)

    Objective: Our aim is to illustrate the incidence of vascular risk factors (VRF) in a cohort of patients with confirmed Parkinson's disease (PD) and characterize…
  • 2022 International Congress

    GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase show evidence of pharmacological efficacy in conduritol β-epoxide (CBE) models of Parkinson’s disease

    B. Guzman, N. Perez, A. Garcia-Collazo, E. Cubero, X. Barril, M. Bellotto, A. Henriques, L. Rouviere, R. Maj (Lugano, Switzerland)

    Objective: Demonstrate the involvement of our structurally targeted allosteric regulator Parkinson’s disease (PD) candidate, GT-02287, in decreasing the CBE-induced neurotoxic effect and in restoring lysosomal…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 16
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley